Nanoparticle-siRNA: A potential cancer therapy?
Nanoparticle-siRNA: A potential cancer therapy?
复制标题
DOI：
10.1016/j.critrevonc.2015.10.015
复制
发表时间：
2016-02
期刊：
影响因子：
--
通讯作者：
Samuel Wang Sherng Young;M. Stenzel;Jia-Lin Yang
中科院分区：
文献类型：
--
作者：
Samuel Wang Sherng Young;M. Stenzel;Jia-Lin Yang
目的探讨短链干扰RNA(SiRNA)递送系统在纳米肿瘤学中的研究进展，特别是包裹siRNA用于肿瘤靶向治疗的纳米颗粒。SiRNA对肿瘤细胞中的致癌基因具有高度的特异性，而纳米粒的应用可以改善递送的稳定性和提高疗效。方法检索文献，检索词为“siRNA”、“纳米粒”、“靶向递送”和“癌症”。这些数据库包括Medline、Embase、Cochrane Review、Pubmed和Scope。结果siRNA抗癌药物利用内源性RNAi机制沉默癌基因表达，从而促进癌症缓解。然而，目前的给药方法效果不佳，需要纳米颗粒的帮助才能成功给药。结论纳米siRNA药物在肿瘤治疗方面具有很大的潜力，但存在纳米颗粒的毒性和偏离靶点的siRNA效应等问题。在这一快速发展和前景看好的纳米siRNA药物领域，还需要进一步的研究。
PurposeTo explore current developments in short interfering RNA (siRNA) delivery systems in nanooncology, in particular nanoparticles that encapsulate siRNA for targeted treatment of cancer. siRNA has a high specificity towards the oncogenic mRNA in cancer cells, while application of nanoparticles can improve stable delivery and enhance efficacy.MethodsA literature search was performed using the terms “siRNA”, “nanoparticles”, “targeted delivery”, and “cancer”. These databases included Medline, Embase, Cochrane Review, Pubmed, and Scopus.ResultssiRNA anti-cancer drugs utilize endogenous RNAi mechanisms to silence oncogene expression, which promotes cancer remission. However, current delivery methods have poor efficacy, requiring assistance by nanoparticles for successful delivery. Recently several preclinical studies have crossed into clinical trials utilizing siRNA nanoparticle therapeutics.ConclusionGreat potential exists for nano-siRNA drugs in cancer treatment, but issues exist with nanoparticle toxicity and off target siRNA effects. Further research is needed in this rapidly developing and promising field of nano-siRNA drugs.